FDA Determines Regulatory Review Period for LEVAQUIN Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Levaquin, a human antibiotic drug, following a submission to the US Department of Commerce for patent extension.